AS1810722 是口服有效的STAT6抑制剂，IC50为 1.9 nM。它是一种稠合双环嘧啶衍生物，对有良好的CYP3A4抑制作用，具有用于过敏性疾病，如哮喘和特应性疾病的研究潜力。

AS1810722 is an orally active and potent STAT6 inhibitor(IC50 :1.9 nM). AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.

AS1810722 showed potent STAT6 inhibition and a good CYP3A4 inhibition profile.?AS1810722 also inhibited in vitro Th2 differentiation without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration.

909561-15-5

C25H25F2N7O

477.52

DMSO:62.5 mg/mL (130.89 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years